Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Aligos Therapeutics (ALGS) Accumulated Depreciation & Amortization (2020 - 2025)

Aligos Therapeutics filings provide 6 years of Accumulated Depreciation & Amortization readings, the most recent being $12.7 million for Q4 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization rose 7.89% to $12.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $12.7 million, a 7.89% increase, with the full-year FY2025 number at $12.7 million, up 7.89% from a year prior.
  • Accumulated Depreciation & Amortization hit $12.7 million in Q4 2025 for Aligos Therapeutics, up from $12.5 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $12.7 million in Q4 2025 to a low of $5.0 million in Q1 2021.
  • Median Accumulated Depreciation & Amortization over the past 5 years was $10.6 million (2023), compared with a mean of $9.8 million.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: surged 71.15% in 2021 and later grew 4.97% in 2025.
  • Aligos Therapeutics' Accumulated Depreciation & Amortization stood at $7.3 million in 2021, then skyrocketed by 31.75% to $9.6 million in 2022, then increased by 12.41% to $10.8 million in 2023, then grew by 9.55% to $11.8 million in 2024, then grew by 7.89% to $12.7 million in 2025.
  • The last three reported values for Accumulated Depreciation & Amortization were $12.7 million (Q4 2025), $12.5 million (Q3 2025), and $12.2 million (Q2 2025) per Business Quant data.